ClinicalTrials.gg
CompletedNCT05151692Updated Oct 26, 2022

A Study of JNJ-80202135 in Healthy Chinese Adult Participants

A Phase 1 interventional study of Nipocalimab in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-26.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Sep 2022, 4 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the pharmacokinetic (PK) of nipocalimab following single intravenous (IV) administration in healthy Chinese participants.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy on the basis of physical examination, medical history, vital signs and 12-lead (ECG) performed at screening. If there are any abnormalities, they must be assessed as not by the investigator and this determination must be recorded in the participant's source documents and initialed by the investigator
  • Healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel hematology, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the participant's source documents and initialed by the investigator
  • Serum immunoglobulin G (IgG) level must be greater than (>) the lower limit of normal at screening
  • (BMI; weight [kilograms {kg}] per height\^2 [meter square {m\^2}]) between 18 and 27.9 kilograms per meter square (kg/m\^2) (inclusive), and body weight not less than 50 kg and less than or equal to (\<=) 110 kg at screening
  • A woman of must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) at Week 0 prior to administration of study intervention

Exclusion criteria

Exclusion Criteria:

  • Known allergies, , or intolerance to nipocalimab or its
  • Serum albumin below the lower limit of normal at screening
  • Use of any prescription or nonprescription medication (including vitamins and herbal supplements), except for paracetamol, acetaminophen, , and hormonal replacement therapy within 14 days before the first dose of the study drug is scheduled until completion of the study
  • Had major surgery, (example: requiring general anesthesia) within 12 weeks before screening, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study or within 8 weeks after the last dose of study intervention administration
  • Has an active, acute or a chronic infection (examples: bronchiectasis, chronic osteomyelitis, chronic pyelonephritis) or requires chronic treatment with anti-infectives (examples: antibiotics, antivirals)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Cohort 1: Nipocalimab

    Participants will receive a single intravenous (IV) dose of nipocalimab Dose 1 on Day 1.

    Drug: Nipocalimab

  • Experimental
    Cohort 2: Nipocalimab

    Participants will receive a single IV dose of nipocalimab Dose 2 on Day 1.

    Drug: Nipocalimab

  • Experimental
    Cohort 3: Nipocalimab

    Participants will receive a single IV dose of nipocalimab Dose 3 on Day 1.

    Drug: Nipocalimab

Interventions

  • Nipocalimab will be administered as an IV infusion.

    Also known as: JNJ-80202135

06

What researchers measure

Primary outcomes

  1. Area Under the Serum Concentration Versus Time Curve From Time Zero to Time of the Last Measurable Concentration (AUC[0-last]) of Nipocalimab

    AUC(0-last) is defined as area under the serum concentration versus time curve from time 0 to time of the last measurable concentration of nipocalimab.

    Time frame: Up to Day 29

  2. Area Under the Analyte Concentration Versus Time Curve From Time Zero to Infinite Time (AUC [0-Infinity]) of Nipocalimab

    AUC (0-Infinity) is defined as area under the analyte concentration versus time curve from time zero to infinite time of nipocalimab.

    Time frame: Up to Day 29

  3. Last Measurable Serum Concentration (Clast) of Nipocalimab

    Clast is defined as last measurable serum concentration of nipocalimab.

    Time frame: Up to Day 29

  4. Maximum Observed Serum Concentration (Cmax) of Nipocalimab

    Cmax is defined as maximum observed serum concentration of nipocalimab.

    Time frame: Up to Day 29

  5. Time of Last Measurable Serum Concentration (Tlast) of Nipocalimab

    Tlast is defined as time of last measurable serum concentration of nipocalimab.

    Time frame: Up To Day 29

  6. Time to Reach the Maximum Observed Serum Concentration (Tmax) of Nipocalimab

    Tmax is defined as time to reach the maximum observed serum concentration of nipocalimab.

    Time frame: Up to Day 29

  7. Apparent Elimination Half-life (T1/2) of Nipocalimab

    T1/2 is defined as apparent elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve of nipocalimab.

    Time frame: Up to Day 29

  8. Total Systemic Clearance (CL) of Nipocalimab

    CL is defined as total systemic clearance of nipocalimab after intravenous (IV) administration.

    Time frame: Up to Day 29

  9. Volume of Distribution (Vz) of Nipocalimab

    Vz is defined as volume of distribution based on terminal phase after IV administration of nipocalimab.

    Time frame: Up to Day 29

Secondary outcomes

  1. Percentage of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.

    Time frame: Up to Day 57

  2. Percentage of Participants with Serious Adverse Event (SAE)

    A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.

    Time frame: Up to Day 57

  3. Percentage of Participants with Adverse Event of Special Interests (AESIs)

    Percentage of participants with AESIs will be reported. Treatment-emergent AEs associated with the following situations are considered as AESI: a) severe or medically significant or immediately life-threatening infections requiring IV anti-infective or operative/invasive intervention or requiring hospitalization or prolongation of existing hospitalization; b) hypoalbuminemia with albumin less than (\<) 20 grams per liter (g/L). Any AE occurring at or after the initial administration of study intervention through end of study is considered to be treatment-emergent.

    Time frame: Up to Day 57

  4. Percentage of Participants with Abnormalities in Physical Examinations

    Percentage of participants with abnormalities in physical examinations (including height and body weight) will be reported.

    Time frame: Up to Day 57

  5. Percentage of Participants with Abnormalities in 12-Lead Electrocardiogram (ECG) Values

    Percentage of participants with abnormalities in 12-lead ECG values will be reported.

    Time frame: Up to Day 57

  6. Percentage of Participants with Abnormalities in Vital Signs

    Percentage of participants with abnormalities in vital signs (temperature axillary, pulse/heart rate, blood pressure \[systolic and diastolic\]) will be reported.

    Time frame: Up to Day 57

  7. Percentage of Participants with Abnormalities in Clinical Laboratory Values

    Percentage of participants with abnormalities in clinical laboratory values (hematology, clinical chemistry, urinalysis) will be reported.

    Time frame: Up to Day 57

  8. Percentage of Participants with Anti-drug Antibodies to Nipocalimab

    Percentage of participants with anti-drug antibodies to nipocalimab will be reported.

    Time frame: Day 1, Day 15, Day 29 and Day 57

  9. Change from Baseline Over Time in Total Immunoglobulin-G (IgG) Serum Levels

    Change from baseline over time in total IgG serum levels will be reported.

    Time frame: Baseline up to Day 57

07

Study locations

1 site
  • Peking University Third Hospital
    Beijing, 100191, China
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Sep 2022, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2021
First posted
Dec 9, 2021
StartActual
May 30, 2022
Primary completionActual
Sep 9, 2022
CompletionActual
Sep 9, 2022
Last update
Oct 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05151692
Responsible party
Sponsor
First posted
Dec 9, 2021
Start date
May 30, 2022
Primary completion
Sep 9, 2022
Completion
Sep 9, 2022
Last update
Oct 26, 2022

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nipocalimab

Start the discussion